PMID- 24001612
OWN - NLM
STAT- MEDLINE
DCOM- 20140116
LR  - 20220409
IS  - 1872-7980 (Electronic)
IS  - 0304-3835 (Linking)
VI  - 342
IP  - 1
DP  - 2014 Jan 1
TI  - Establishment and characterization of a novel HPV-negative laryngeal squamous 
      cell carcinoma cell line, FD-LSC-1, with missense and nonsense mutations of TP53 
      in the DNA-binding domain.
PG  - 92-103
LID - S0304-3835(13)00626-5 [pii]
LID - 10.1016/j.canlet.2013.08.041 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is a common malignancy in China; 
      however, publically available LSCC cell lines are few and not established from 
      Chinese populations. Hence, novel and well-characterized LSCC cell lines of 
      Chinese origin are urgently needed to provide researchers with a comprehensive 
      database for LSCC research. From 40 cases of LSCC, we established a novel cell 
      line that was maintained for more than 100 passages in vitro and was found to 
      have typical epithelial morphology and ultrastructure. In-depth characterization 
      analysis revealed polyploidy in DNA content; a doubling time of some 24h; high 
      tumorigenicity in immunodeficient mice; higher invasive potential and more 
      sensitive to radiation and cisplatin compared with HeLa cell line; upregulated 
      Ki67, Notch1, EGFR, and CK5 protein levels; negative infection of human 
      papillomavirus (HPV) and mycoplasma; expression of head and neck squamous cell 
      carcinoma (HNSCC) biomarkers; mutations of TP53 in exons 5 and 8; a near-triploid 
      karyotype with complex structural aberrations; and dozens of dysregulated genes 
      and miRNAs. Cell authentication testing by the American Type Culture Collection 
      (ATCC) confirmed the human origin of this cell line. Our findings indicate that a 
      novel and well-differentiated LSCC cell line recapitulating the primary tumor's 
      malignant characteristics is established and well characterized. It does not 
      match any cell lines within the ATCC database and helps to elucidate the 
      molecular pathogenesis of LSCC.
CI  - Copyright (c) 2013 Elsevier Ireland Ltd. All rights reserved.
FAU - Wu, Chun-Ping
AU  - Wu CP
AD  - Department of Otolaryngology-Head and Neck Surgery, Eye, Ear, Nose and Throat 
      Hospital, Fudan University, Shanghai 200031, China.
FAU - Zhou, Liang
AU  - Zhou L
FAU - Gong, Hong-Li
AU  - Gong HL
FAU - Du, Huai-Dong
AU  - Du HD
FAU - Tian, Jie
AU  - Tian J
FAU - Sun, Shan
AU  - Sun S
FAU - Li, Jin-Yan
AU  - Li JY
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130831
PL  - Ireland
TA  - Cancer Lett
JT  - Cancer letters
JID - 7600053
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Codon, Nonsense)
RN  - 0 (MicroRNAs)
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - Q20Q21Q62J (Cisplatin)
SB  - IM
MH  - Aged
MH  - Alphapapillomavirus/genetics
MH  - Animals
MH  - Antineoplastic Agents/pharmacology
MH  - Base Sequence
MH  - Binding Sites
MH  - Carcinoma, Squamous Cell/genetics/*pathology
MH  - Cell Line, Tumor/drug effects/*physiology/radiation effects
MH  - Cell Proliferation
MH  - Cell Shape
MH  - Cisplatin/pharmacology
MH  - Codon, Nonsense
MH  - DNA Mutational Analysis
MH  - Epiglottis/pathology
MH  - Gene Expression Regulation, Neoplastic
MH  - Genotype
MH  - Humans
MH  - Karyotype
MH  - Laryngeal Neoplasms/genetics/*pathology
MH  - Male
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - MicroRNAs/genetics/metabolism
MH  - Mutation, Missense
MH  - Neoplasm Transplantation
MH  - Protein Structure, Tertiary
MH  - Radiation Tolerance
MH  - Tumor Suppressor Protein p53/chemistry/*genetics
OTO - NOTNLM
OT  - Carcinoma
OT  - Cell line
OT  - Characterization
OT  - Establishment
OT  - Laryngeal neoplasms
OT  - Squamous cell
EDAT- 2013/09/05 06:00
MHDA- 2014/01/17 06:00
CRDT- 2013/09/05 06:00
PHST- 2013/06/12 00:00 [received]
PHST- 2013/08/20 00:00 [revised]
PHST- 2013/08/24 00:00 [accepted]
PHST- 2013/09/05 06:00 [entrez]
PHST- 2013/09/05 06:00 [pubmed]
PHST- 2014/01/17 06:00 [medline]
AID - S0304-3835(13)00626-5 [pii]
AID - 10.1016/j.canlet.2013.08.041 [doi]
PST - ppublish
SO  - Cancer Lett. 2014 Jan 1;342(1):92-103. doi: 10.1016/j.canlet.2013.08.041. Epub 
      2013 Aug 31.